Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

By M. Posner, D. Hershock, C. Blajman. New England Journal of Medicine, 2007

1,627 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. (2009, neutral): “Since taxane-based induction chemotherapy also proved, in three recent randomised trials [16–18], to be superior to the reference 5-FU-platin-based induction chemotherapy, it is not possible to rule out that the benefit due to induction chemotherapy could be more pronounced that it appears to be in ”
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. (2011, result): “It should also be of note that trials using taxane, cisplatinum and 5-fluorouracil (TPF) as neoadjuvant chemotherapy are not included in this database so the results cannot be applied in this setting [15,16].”
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas (2014, background): “All patients with HNSCC are treated with a largely uniform approach based on stage and anatomic location, typically using surgery, radio-, and chemotherapy alone or in combination (9).”
An update on larynx cancer (2017, background): “006) improved with TPF.(76) A subset analysis of TAX 324 examining the laryngeal and hypopharyngeal cancers confirmed the PFS and OS benefit as well as improved laryngeal preservation with TPF.”